• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

引言:欧洲癌症治愈和生存率研究(EUROCARE II)

Introduction: the EUROCARE II Study.

作者信息

Berrino F, Gatta G, Chessa E, Valente F, Capocaccia R

机构信息

Division of Epidemiology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan.

出版信息

Eur J Cancer. 1998 Dec;34(14 Spec No):2139-53. doi: 10.1016/s0959-8049(98)00334-7.

DOI:10.1016/s0959-8049(98)00334-7
PMID:10070280
Abstract

This introduction provides a general overview of the aims, methods and procedures used in the EUROCARE II study and the types of analyses presented in each article of this Special Issue of the European Journal of Cancer. The main aims of the EUROCARE II project are the updating of the survival database of the European Cancer Registries, the study of recent trends in relative survival rates and the interpretation of the survival differences observed both in time and across populations. Once having completed the preliminary stage of data checking, a total of 3,473,659 individual records from patients of all cancer sites, diagnosed between 1978 and 1989 and provided by 45 cancer registries in 17 European countries were accepted to build up the EUROCARE database. The quality of these data, in terms of the accuracy of the diagnosis and the validity of vital status assessment, was checked by indirect indicators, based on cross-validation analysis of consistency of the relevant variables. Statistical analysis was based on age-specific relative survival rates, computed for each cancer sites as the ratio of observed survival to the expected survival of the general population of the same area, gender and age, according to the Hakulinen method. An estimate of the European survival was computed as a weighted mean of the corresponding survival of the different countries, using as weights the expected yearly number of incident cases in each country. For comparison purposes, age-standardised survival was also calculated for Europe and for each country involved in the study.

摘要

本引言概述了欧洲癌症研究与治疗组织(EUROCARE)II 期研究中所采用的目标、方法和程序,以及《欧洲癌症杂志》这一特刊每篇文章中呈现的分析类型。EUROCARE II 项目的主要目标是更新欧洲癌症登记处的生存数据库,研究相对生存率的近期趋势,并解读在不同时间和不同人群中观察到的生存差异。在完成数据检查的初步阶段后,来自 17 个欧洲国家 45 个癌症登记处提供的、1978 年至 1989 年间诊断的所有癌症部位患者的总计 3,473,659 条个体记录被纳入以建立 EUROCARE 数据库。这些数据在诊断准确性和生命状态评估有效性方面的质量,通过基于相关变量一致性交叉验证分析的间接指标进行了检查。统计分析基于特定年龄的相对生存率,根据哈库利宁方法,针对每个癌症部位计算为观察到的生存率与同一地区、性别和年龄的一般人群预期生存率的比值。欧洲生存率的估计值是通过将不同国家相应生存率的加权平均值计算得出,权重为每个国家每年预期的发病病例数。为了便于比较,还计算了欧洲以及参与该研究的每个国家的年龄标准化生存率。

相似文献

1
Introduction: the EUROCARE II Study.引言:欧洲癌症治愈和生存率研究(EUROCARE II)
Eur J Cancer. 1998 Dec;34(14 Spec No):2139-53. doi: 10.1016/s0959-8049(98)00334-7.
2
The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis.EUROCARE-3数据库:数据收集、标准化、质量控制及统计分析方法
Ann Oncol. 2003;14 Suppl 5:v14-27. doi: 10.1093/annonc/mdg751.
3
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.意大利癌症数据——2015年报告:意大利罕见癌症的负担
Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035.
4
The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis.欧洲癌症生存情况EUROCARE-4数据库:数据标准化、质量控制及统计分析方法
Eur J Cancer. 2009 Apr;45(6):909-30. doi: 10.1016/j.ejca.2008.11.003. Epub 2009 Jan 6.
5
Relative survival in elderly European cancer patients: evidence for health care inequalities. The EUROCARE Working Group.欧洲老年癌症患者的相对生存率:医疗保健不平等的证据。欧洲癌症和治愈评估(EUROCARE)工作组
Crit Rev Oncol Hematol. 2000 Sep;35(3):161-79. doi: 10.1016/s1040-8428(00)00075-5.
6
Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study.1995 - 1999年确诊的欧洲成年患者中八大主要癌症及所有癌症合并的生存率:EUROCARE - 4研究结果。
Lancet Oncol. 2007 Sep;8(9):773-83. doi: 10.1016/S1470-2045(07)70245-0.
7
Childhood malignancies in the EUROCARE study: the database and the methods of survival analysis.
Eur J Cancer. 2001 Apr;37(6):678-86. doi: 10.1016/s0959-8049(01)00043-0.
8
Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data.欧洲近期癌症生存率:基于EUROCARE-4数据的2000 - 2002年期间分析
Lancet Oncol. 2007 Sep;8(9):784-96. doi: 10.1016/S1470-2045(07)70246-2.
9
Italian cancer figures, report 2012: Cancer in children and adolescents.《2012年意大利癌症数据报告:儿童和青少年癌症》
Epidemiol Prev. 2013 Jan-Feb;37(1 Suppl 1):1-225.
10
Survival for cancer patients in Europe.欧洲癌症患者的生存率。
Ann Ist Super Sanita. 2009;45(3):315-24.

引用本文的文献

1
Impact of guideline therapy on survival of patients with stage I-III epithelioid mesothelioma.指南治疗对Ⅰ-Ⅲ期上皮样间皮瘤患者生存的影响。
J Thorac Dis. 2023 Dec 30;15(12):6661-6673. doi: 10.21037/jtd-23-1334. Epub 2023 Dec 26.
2
Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.间皮瘤组织学亚型对监测、流行病学和最终结果数据库中预后的影响。
J Surg Res. 2015 Jun 1;196(1):23-32. doi: 10.1016/j.jss.2015.01.043. Epub 2015 Jan 29.
3
When do changes in cancer survival mean progress? The insight from population incidence and mortality.
癌症生存率的变化何时意味着取得了进展?来自人群发病率和死亡率的见解。
J Natl Cancer Inst Monogr. 2014 Nov;2014(49):187-97. doi: 10.1093/jncimonographs/lgu014.
4
Fully covered removable nitinol self-expandable metal stents (SEMS) in malignant strictures of the esophagus: a multicenter analysis.完全覆膜可回收镍钛形状记忆合金支架(SEMS)治疗食管恶性狭窄:多中心分析。
Surg Endosc. 2012 Jun;26(6):1664-9. doi: 10.1007/s00464-011-2089-z. Epub 2011 Dec 17.
5
Patient and tumour characteristics, management, and age-specific survival in women with breast cancer in the East of England.英格兰东部女性乳腺癌患者的特征、肿瘤特征、管理及年龄特异性生存。
Br J Cancer. 2011 Feb 15;104(4):564-70. doi: 10.1038/bjc.2011.14.
6
Survival after neoadjuvant therapy compared with surgery alone for resectable esophageal cancer in a population-based study.在一项基于人群的研究中,新辅助治疗与单纯手术治疗可切除食管癌后的生存率比较。
World J Surg. 2006 Dec;30(12):2182-90; discussion 2191-2. doi: 10.1007/s00268-006-0016-6.
7
Effect of a multidisciplinary lung investigation day on a rapid access lung cancer service.多学科肺部检查日对快速通道肺癌服务的影响。
Postgrad Med J. 2006 Jun;82(968):414-6. doi: 10.1136/pgmj.2005.041699.
8
Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.欧洲抗癌药物十年营销批准情况:监管政策与指导文件需在不同压力间找到平衡。
Br J Cancer. 2005 Sep 5;93(5):504-9. doi: 10.1038/sj.bjc.6602750.
9
Chemoradiotherapy for colorectal cancer.结直肠癌的放化疗
Gut. 2005 Aug;54(8):1194-202. doi: 10.1136/gut.2004.062745.
10
Efficacy, safety, and cost of new anticancer drugs.新型抗癌药物的疗效、安全性及成本
BMJ. 2002 Aug 3;325(7358):269-71. doi: 10.1136/bmj.325.7358.269.